Latest news with #PfizerGulf
Web Release
08-05-2025
- Health
- Web Release
New Era for Hemophilia Care in the UAE: Pfizer Introduces First Prefilled Injectable Therapy
By Editor_wr On May 8, 2025 Pfizer announced today the launch of a new and innovative therapy for people living with hemophilia in the UAE. This marks a significant advancement in care for individuals affected by this rare and serious bleeding disorder. Hemophilia is a rare genetic bleeding disorder in which the blood fails to clot properly, leading to prolonged bleeding that can be either spontaneous or occur after an injury[1]. Unlike traditional clotting factor replacements, Pfizer's new therapy targets the tissue factor pathway inhibitor (TFPI), a natural anticoagulant protein. By inhibiting TFPI, the treatment helps restore balance to the body's clotting process, reducing the frequency of bleeding episodes. This advanced therapy is administered once a week through a simple injection under the skin using a prefilled autoinjector pen. It is the first prefilled injectable therapy available in the UAE, designed to make treatment more convenient and accessible for patients, while reducing the burden of frequent infusions. Dr. Nadine Tarcha, Pfizer Gulf Medical Director, said: 'The introduction of this therapy reflects Pfizer's ongoing commitment to improving the lives of people with rare diseases. By combining scientific innovation with a more convenient delivery method, we aim to empower individuals with hemophilia to live with greater confidence and improved quality of life.' According to the World Federation of Hemophilia's 2023 Annual Global Survey[2], more than 32,000 in the Eastern Mediterranean region have been diagnosed with hemophilia. This represents less than half of the expected number of cases, suggesting that many individuals remain undiagnosed or lack access to appropriate care. These findings emphasize the importance of early diagnosis and patient-friendly treatment options that can support better long-term outcomes. The introduction of this therapy supports the UAE's broader healthcare vision, which prioritizes access to innovative treatments and improved quality of care for people living with complex and rare conditions. Patients are encouraged to speak with their healthcare provider to determine whether this treatment may be appropriate for their condition. Comments are closed.
Emirates 24/7
29-04-2025
- Health
- Emirates 24/7
Department of Health – Abu Dhabi, Pfizer host high-level workshop to advance real world data in healthcare research
The Department of Health – Abu Dhabi (DoH) in collaboration with Pfizer Gulf hosted a specialised workshop titled 'Harnessing the Power of Real World Data in Healthcare Research,' as part of the strategic Memorandum of Understanding (MoU) signed between the two entities in 2024. The MoU underscores a shared commitment to strengthening Abu Dhabi's position as a global hub for healthcare innovation, by advancing real world data (RWD) capabilities and enabling data-driven, evidence-based decision-making. The workshop brought together more than 60 researchers, data scientists, pharmacists, and healthcare professionals from across Abu Dhabi's leading hospitals and academic institutions to explore how real-world evidence (RWE) can be leveraged to advance research, improve health outcomes, and enable more personalized care. The event served as a platform to foster knowledge exchange and scientific dialogue, and to support Abu Dhabi's ambition to become a global centre for health and life sciences. Through the MoU, Pfizer and DoH are working jointly to enhance real-world data (RWD) capabilities, with a focus on driving local evidence generation and building research capacity that addresses both national and global healthcare priorities. Dr. Nadine Tarcha, Medical Director at Pfizer Gulf, highlighted the company's role in shaping the future of healthcare research through meaningful partnerships. 'At Pfizer, we believe real-world data is key to generating insights that complement clinical trials and accelerate patient-centred innovation. Through this collaboration with the Department of Health, we aim to empower local research, strengthen evidence generation, and improve access to better health outcomes.' The workshop agenda included a range of expert-led discussions on the use of RWD from national databases, differences between RWE and traditional clinical trials, study design and bias, regulatory considerations, and governance models for data access. A panel discussion was also held featuring representatives from the Department of Health, the UAE Genome Programme, M42, and global Pfizer RWE leaders to explore the potential of Abu Dhabi's Trusted Research Environment in advancing scientific discovery. This initiative is part of a broader effort under the MoU to foster long-term public-private partnerships that enhance Abu Dhabi's global competitiveness in biomedical research, genomics, and precision medicine. It reinforces both entities' commitment to advancing data-driven solutions that improve health outcomes in the UAE and beyond. Follow Emirates 24|7 on Google News.
Al Etihad
28-04-2025
- Health
- Al Etihad
DoH, Pfizer host high-level workshop to advance real world data in healthcare research
28 Apr 2025 15:06 ABU DHABI (WAM)The Department of Health – Abu Dhabi (DoH), in collaboration with Pfizer Gulf, hosted a specialised workshop titled 'Harnessing the Power of Real World Data in Healthcare Research', as part of the strategic Memorandum of Understanding (MoU) signed between the two entities in MoU underscores a shared commitment to strengthening Abu Dhabi's position, as a global hub for healthcare innovation, by advancing real-world data capabilities and enabling data-driven, evidence-based workshop brought together more than 60 researchers, data scientists, pharmacists, and healthcare professionals from across Abu Dhabi's leading hospitals and academic institutions to explore how real-world evidence can be leveraged to advance research, improve health outcomes, and enable more personalised event served as a platform to foster knowledge exchange and scientific dialogue, and to support Abu Dhabi's ambition to become a global centre for health and life sciences. Through the MoU, Pfizer and DoH are working jointly to enhance real-world data capabilities, with a focus on driving local evidence generation and building research capacity that addresses both national and global healthcare Nadine Tarcha, Medical Director at Pfizer Gulf, highlighted the company's role in shaping the future of healthcare research through meaningful partnerships, 'At Pfizer, we believe real-world data is key to generating insights that complement clinical trials and accelerate patient-centred innovation. Through this collaboration with the Department of Health, we aim to empower local research, strengthen evidence generation, and improve access to better health outcomes.'The workshop agenda included a range of expert-led discussions on the use of real-world data from national databases, differences between real-world evidence and traditional clinical trials, study design and bias, regulatory considerations, and governance models for data access.A panel discussion was also held featuring representatives from the Department of Health, the UAE Genome Programme, M42, and global Pfizer real-world evidence leaders to explore the potential of Abu Dhabi's Trusted Research Environment in advancing scientific discovery. This initiative is part of a broader effort under the MoU to foster long-term public-private partnerships that enhance Abu Dhabi's global competitiveness in biomedical research, genomics, and precision medicine. It reinforces both entities' commitment to advancing data-driven solutions that improve health outcomes in the UAE and beyond.
Zawya
28-04-2025
- Health
- Zawya
Pfizer and the Department of Health – Abu Dhabi hosted a high-level workshop to advance real world data in healthcare research
Abu Dhabi, UAE: Pfizer Gulf in collaboration with The Department of Health – Abu Dhabi (DoH), hosted a specialized workshop titled 'Harnessing the Power of Real World Data in Healthcare Research,' as part of the strategic Memorandum of Understanding (MoU) signed between the two entities in 2024. The MoU underscores a shared commitment to strengthening Abu Dhabi's position as a global hub for healthcare innovation, by advancing real world data (RWD) capabilities and enabling data-driven, evidence-based decision making. The workshop brought together more than 60 researchers, data scientists, pharmacists, and healthcare professionals from across Abu Dhabi's leading hospitals and academic institutions to explore how real-world evidence (RWE) can be leveraged to advance research, improve health outcomes, and enable more personalized care. The event served as a platform to foster knowledge exchange and scientific dialogue, and to support Abu Dhabi's ambition to become a global centre for health and life sciences. Through the MoU, Pfizer and DoH are working jointly to enhance real world data (RWD) capabilities, with a focus on driving local evidence generation and building research capacity that addresses both national and global healthcare priorities. Dr. Nadine Tarcha, Medical Director at Pfizer Gulf, highlighted the company's role in shaping the future of healthcare research through meaningful partnerships. 'At Pfizer, we believe real world data is key to generating insights that complement clinical trials and accelerate patient-centred innovation. Through this collaboration with the Department of Health, we aim to empower local research, strengthen evidence generation, and improve access to better health outcomes.' The workshop agenda included a range of expert-led discussions on the use of RWD from national databases, differences between RWE and traditional clinical trials, study design and bias, regulatory considerations, and governance models for data access. A panel discussion was also held featuring representatives from the Department of Health, the UAE Genome Program, M42, and global Pfizer RWE leaders to explore the potential of Abu Dhabi's Trusted Research Environment in advancing scientific discovery. This initiative is part of a broader effort under the MoU to foster long-term public-private partnerships that enhance Abu Dhabi's global competitiveness in biomedical research, genomics, and precision medicine. It reinforces both entities' commitment to advancing data-driven solutions that improve health outcomes in the UAE and beyond. About Pfizer Gulf At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety, and value in the discovery, development, and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments, and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments, and local communities to support and expand access to reliable, affordable health care around the world. For more than 175 years, we have worked to make a difference for all who rely on us. About the Department of Health – Abu Dhabi The Department of Health – Abu Dhabi is the regulative body of the healthcare sector in the Emirate of Abu Dhabi. Committed to ensuring excellence in healthcare, DoH monitors the health status of the population while shaping the regulatory framework for the health system. This includes inspecting against regulations, enforcing standards and encouraging the adoption of world-class best practices and performance targets by all healthcare providers in the Emirate. Abu Dhabi remains dedicated to shaping the future of healthcare by establishing an intelligent and sustainable ecosystem that prioritises health, longevity and quality of life for all community members. Leveraging state-of-the-art infrastructure and cutting-edge capabilities, DoH continues to develop and implement initiatives and programmes in line with its strategic focus areas, Healthy Population, Best-in-Class Care and Resilience and Innovation. These efforts reflect DoH's unwavering commitment to predicting, preventing and personalising healthcare for every individual.
Web Release
28-04-2025
- Health
- Web Release
Pfizer and the Department of Health – Abu Dhabi Hosted a High-Level Workshop to Advance Real World Data in Healthcare Research
By Editor_wr On Apr 28, 2025 Pfizer Gulf in collaboration with The Department of Health – Abu Dhabi (DoH), hosted a specialized workshop titled 'Harnessing the Power of Real World Data in Healthcare Research,' as part of the strategic Memorandum of Understanding (MoU) signed between the two entities in 2024. The MoU underscores a shared commitment to strengthening Abu Dhabi's position as a global hub for healthcare innovation, by advancing real world data (RWD) capabilities and enabling data-driven, evidence-based decision making. The workshop brought together more than 60 researchers, data scientists, pharmacists, and healthcare professionals from across Abu Dhabi's leading hospitals and academic institutions to explore how real-world evidence (RWE) can be leveraged to advance research, improve health outcomes, and enable more personalized care. The event served as a platform to foster knowledge exchange and scientific dialogue, and to support Abu Dhabi's ambition to become a global centre for health and life sciences. Through the MoU, Pfizer and DoH are working jointly to enhance real world data (RWD) capabilities, with a focus on driving local evidence generation and building research capacity that addresses both national and global healthcare priorities. Dr. Nadine Tarcha, Medical Director at Pfizer Gulf, highlighted the company's role in shaping the future of healthcare research through meaningful partnerships. 'At Pfizer, we believe real world data is key to generating insights that complement clinical trials and accelerate patient-centred innovation. Through this collaboration with the Department of Health, we aim to empower local research, strengthen evidence generation, and improve access to better health outcomes.' The workshop agenda included a range of expert-led discussions on the use of RWD from national databases, differences between RWE and traditional clinical trials, study design and bias, regulatory considerations, and governance models for data access. A panel discussion was also held featuring representatives from the Department of Health, the UAE Genome Program, M42, and global Pfizer RWE leaders to explore the potential of Abu Dhabi's Trusted Research Environment in advancing scientific discovery. This initiative is part of a broader effort under the MoU to foster long-term public-private partnerships that enhance Abu Dhabi's global competitiveness in biomedical research, genomics, and precision medicine. It reinforces both entities' commitment to advancing data-driven solutions that improve health outcomes in the UAE and beyond. Comments are closed.
